EFFECTS OF INHALED CORTICOSTEROIDS IN STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE : A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/7k51ta96Keywords:
Effects, inhaled corticosteroids, stable, COPDAbstract
Background: Inhaled corticosteroids aid COPD patients by improving lung function and reducing exacerbations. The combination of ICS and LABA is more effective than LABA alone, indicating that blood eosinophilia influences therapy efficacy. Patients with low peak inspiratory flow may not receive enough delivery, necessitating the use of spacers to enhance inhaler actuation and inspiration timing. This study aims to systematically review the literature on the effects of inhaled corticosteroids in stable COPD in the last 10 years.
Methods: This systematic review used the PRISMA 2020 principles and examined full-text English literature published between 2014 and 2024. Submissions without a DOI were not taken into consideration, nor were editorials and review papers from the same publication. Online resources like PubMed, SagePub, and ScienceDirect were used to compile the literature.
Result: Initially, our study team gathered over 60,000 papers from reputable websites such as PubMed, SagePub, and ScienceDirect. Only five papers were found to be directly relevant to our ongoing systematic review after a thorough three-level filtering approach. These publications were then selected for further research through full-text reading.
Conclusion: ICS is an effective treatment for COPD because it reduces inflammation, improves airway remodelling, and lowers bacterial load. Higher doses are more effective, because budesonide inhalation enhances lung function.
References
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Fabbri, L. M., Frith, P., Halpin, D. M. G., & Victorina, M. (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. 1–74.
Pascoe, S., Locantore, N., Dransfi, M. T., Barnes, N. C., & Pavord, I. D. (2015). Blood eosinophil counts , exacerbations , and response to the addition of inhaled fl uticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease : a secondary analysis of data from two parallel randomised controlled trials. 2600(15), 1–8. https://doi.org/10.1016/S2213-2600(15)00106-X
(GOLD), G. I. for C. O. L. D. (2024). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease Prevention of Chronic Obstructive Pulmonary Disease.
Mathioudakis, A. G., Bikov, A., Foden, P., Lahousse, L., Brusselle, G., & Singh, D. (2020). Early View Original article Change in blood eosinophils following treatment with inhaled corticosteroids may predict long- term clinical response in COPD.
Barnes, P. J., Burney, P. G. J., Silverman, E. K., Celli, B. R., Vestbo, J., Wedzicha, J. A., & Wouters, E. F. M. (2015). Chronic obstructive pulmonary disease. Nature Publishing Group, December, 1–22. https://doi.org/10.1038/nrdp.2015.76
Km, K., & Seniukovich, A. (2014). Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease ( Review ). 3.
Huber, B., Keller, C., Jenkins, M., Raza, A., & Aurivillius, M. (2022). Effect of inhaled budesonide/formoterol fumarate dihydrate delivered via two different devices on lung function in patients with COPD and low peak inspiratory flow. Therapeutic Advances in Respiratory Disease, 16, 17534666221107312. https://doi.org/10.1177/17534666221107312
Mahler, D. A. (2017). Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic Obstructive Pulmonary Disease. Annals of American Thoracic Society, 1–17.
Altman, P., Wehbe, L., Dederichs, J., Guerin, T., Ament, B., Moronta, M. C., Pino, A. V., & Goyal, P. (2018). Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulmonary Medicine, 18(1), 100. https://doi.org/10.1186/s12890-018-0662-0
Vincken, W., Levy, M. L., Scullion, J., Usmani, O. S., Dekhuijzen, P. N. R., & Corrigan, C. J. (n.d.). Spacer devices for inhaled therapy : why use them , and how ? 1–10. https://doi.org/10.1183/23120541.00065-2018
Cheng, S.-L., Su, K.-C., Wang, H.-C., Perng, D.-W., & Yang, P.-C. (2014). Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. Drug Design, Development and Therapy, 8, 601–607. https://doi.org/10.2147/DDDT.S63100
Soltani, A., Walters, E. H., Reid, D. W., Shukla, S. D., Nowrin, K., Ward, C., Muller, H. K., & Sohal, S. S. (2016). Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD. International Journal of Chronic Obstructive Pulmonary Disease, 11, 2359–2367. https://doi.org/10.2147/COPD.S113176
Contoli, M., Pauletti, A., Rossi, M. R., Spanevello, A., Casolari, P., Marcellini, A., Forini, G., Gnesini, G., Marku, B., Barnes, N., Rizzi, A., Curradi, G., Caramori, G., Morelli, P., & Papi, A. (2017). Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. The European Respiratory Journal, 50(4). https://doi.org/10.1183/13993003.00451-2017
Zanini, A., Chetta, A., Saetta, M., Baraldo, S., Castagnetti, C., Nicolini, G., Neri, M., Olivieri, D., & Foundation, S. M. (n.d.). Bronchial vascular remodelling in patients with COPD and its relationship with inhaled steroid treatment. https://doi.org/10.1136/thx.2009.114629
Soltani, A., Wood-baker, R., Sohal, S. S., Muller, H. K., Reid, D., & Walters, E. H. (2012). Reticular Basement Membrane Vessels Are Increased in COPD Bronchial Mucosa by Both Factor VIII and Collagen IV Immunostaining and Are Hyperpermeable. 2012. https://doi.org/10.1155/2012/958383
Stolberg, V. R., Mccubbrey, A. L., Christine, M., Brown, J. P., Crudgington, S. W., Taitano, H., Saxton, B. L., Mancuso, P., & Jeffrey, L. (2015). Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function. https://doi.org/10.4049/jimmunol.1402217
Lee, J., Machin, M., Russell, K. E., Pavlidis, S., Zhu, J., Barnes, P. J., Chung, K. F., Adcock, I. M., & Durham, A. L. (2016). Corticosteroid modulation of immunoglobulin expression and B-cell function in COPD. 1–13. https://doi.org/10.1096/fj.201500135
Hartjes, F. L. J., Vonk, J. U. M., Faiz, A. L. E. N., Hiemstra, P. I. S., Lapperre, T. H. S., Kerstjens, H. U. I. B. A. M., Postma, D. I. S., & Berge, M. A. Van Den. (2018). Predictive value of eosinophils and neutrophils on clinical effects of ICS in COPD. 1–9. https://doi.org/10.1111/resp.13312
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Anggy Apriyanto, Lusiana Nova
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
